KESIMPTA (ofatumumab) by Novartis is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2009.
Drug data last refreshed 31m ago · AI intelligence enriched 1mo ago
KESIMPTA (ofatumumab) is a CD20-directed monoclonal antibody administered subcutaneously for treatment of B-cell malignancies and autoimmune conditions. It works by binding to CD20 on B-cell surfaces, inducing cytolysis and depletion of B cells. The subcutaneous formulation provides a patient-convenient alternative to intravenous administration.
Product facing loss of exclusivity with competitive pressure at 30%; team likely in transition planning and market defense mode rather than growth investment.
CD20-directed Antibody Interactions
CD20-directed Cytolytic Antibody
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
Worked on KESIMPTA at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Novartis is hiring 1 role related to this product
Working on KESIMPTA offers exposure to a mature, competitive CD20 space with established clinical utility but limited growth headroom. Role focus shifts toward defending market share, managing payer relationships, and optimizing existing market rather than building new patient populations.